Findings from three studies provide further support for the effectiveness and safety of COVID-19 vaccines in young people with rheumatic and musculoskeletal diseases.
The proportion of people with rheumatic and musculoskeletal diseases experiencing severe COVID-19 has declined since the beginning of the pandemic, particularly during the recent Omicron wave, US researchers report.
Holding methotrexate treatment for 2 weeks following administration of a booster dose of vaccines against SARS-CoV-2 significantly improves the humoral immune response to vaccination, suggest findings from a randomized controlled trial.
